ABSTRACT
Fundamento y objetivo. Los fármacosantirretrovirales pueden ser causa de interaccionesmedicamentosas.Material y métodos. Se describen tres casosclínicos de pacientes infectados por VIH en los quedebido a una interacción farmacocinética se produjoun efecto adverso clínicamente relevante.Resultados. Caso 1: mujer de 43 años en tratamientocon tenofovir DF, emtricitabina y lopinavir/ritonavirque presenta isquemia de ambos miembros superioressecundaria a síndrome ergotamínico. Caso 2: varón de54 años en tratamiento con zidovudina, lamivudina ylopinavir/ritonavir que presenta síndrome de Cushingsecundario al uso de fluticasona inhalada. Caso 3:varón de 45 años en tratamiento con tenofovir DF,emtricitabina y atazanavir/ritonavir que presenta unfracaso virológico como consecuencia del consumoconcomitante de omeprazol.Conclusiones. Se deben considerar las potencialesinteracciones medicamentosas de los fármacosantirretrovirales cuando se administra otro fármacoconcomitantemente, especialmente cuando algunode éstos es inductor o inhibidor enzimático delcitocromo P-450
Background and aim. Antiretroviral drugs cancause drug interactions.Material and methods. Three clinical cases aredescribed regarding HIV-infected patients in whicha clinically relevant adverse effect occurred due to apharmacokinetic interaction.Results. Case 1: A 43-year old woman being treatedwith tenofovir DF, emtricitabine andlopinavir/ritonavir who presents ischemia in bothupper extremities following an ergotaminesyndrome. Case 2: A 54-year old man being treatedwith zidovudine, lamivudine and lopinavir/ritonavirwho presents Cushing syndrome following to use ofinhaled fluticasone. Case 3: A 45-year old manbeing treated with tenofovir DF, emtricitabine andatazanavir/ritonavir who presents a virologicalfailure as consequence of concomitant use ofomeprazole.Conclusions. Potential drug interactions must beconsidered when other concomitant drugs are usedwith antiretroviral therapy especially when one ofthese is a P 450 cytochrome enzymatic inductor orinhibitor
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Anti-Retroviral Agents/adverse effects , Drug Interactions , HIV Infections/drug therapy , Antiretroviral Therapy, Highly Active/adverse effects , Cytochrome P-450 Enzyme System/pharmacokinetics , Omeprazole/adverse effects , Ergotamines/adverse effects , Adrenal Cortex Hormones/adverse effectsABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Deglutition Disorders/etiology , Hyperostosis, Diffuse Idiopathic Skeletal/diagnosis , Tomography, X-Ray Computed , Analgesics/therapeutic use , Anti-Inflammatory Agents/therapeutic useABSTRACT
Two new antiretroviral drugs belonging to a new drug family have recently been marketed in Spain. These are maraviroc (CCR5 correceptor inhibitor) and raltegravir (integrase inhibitor). These have the advantage of not presenting crossed resistance with other previously administered antiretroviral drugs, converting them into the cornerstone of the rescue treatment in the patient infected by a multiresistant viral strain. The scientific evidence available on these two drugs is reviewed in this work and its indications in the HIV infected patient are discussed.
Subject(s)
CCR5 Receptor Antagonists , Cyclohexanes/therapeutic use , HIV Fusion Inhibitors/therapeutic use , Integrase Inhibitors/therapeutic use , Pyrrolidinones/therapeutic use , Triazoles/therapeutic use , Humans , Maraviroc , Raltegravir PotassiumABSTRACT
BACKGROUND AND AIM: Antiretroviral drugs can cause drug interactions. MATERIAL AND METHODS: Three clinical cases are described regarding HIV-infected patients in which a clinically relevant adverse effect occurred due to a pharmacokinetic interaction. RESULTS: Case 1: A 43-year old woman being treated with tenofovir DF, emtricitabine and lopinavir/ritonavir who presents ischemia in both upper extremities following an ergotamine syndrome. Case 2: A 54-year old man being treated with zidovudine, lamivudine and lopinavir/ritonavir who presents Cushing syndrome following to use of inhaled fluticasone. Case 3: A 45-year old man being treated with tenofovir DF, emtricitabine and atazanavir/ritonavir who presents a virological failure as consequence of concomitant use of omeprazole. CONCLUSIONS: Potential drug interactions must be considered when other concomitant drugs are used with antiretroviral therapy especially when one of these is a P 450 cytochrome enzymatic inductor or inhibitor.
Subject(s)
Anti-Retroviral Agents/adverse effects , Anti-Retroviral Agents/therapeutic use , HIV Infections/drug therapy , Adult , Anti-Retroviral Agents/pharmacokinetics , Cytochrome P-450 Enzyme System/metabolism , Drug Interactions , Female , HIV Infections/metabolism , Humans , Male , Middle AgedABSTRACT
BACKGROUND AND OBJECTIVE: Tuberculosis is an infectious disease currently having great importance in the daily clinical practice in Spain. Some cases of active tuberculosis are not identified until after the patient had died and an autopsy has been performed. This study has analyzed the clinical and pathological characteristics of patients diagnosed with active tuberculosis in the autopsy. MATERIAL AND METHOD: We reviewed all the autopsies performed in the University Hospital 12 de Octubre of Madrid between 1974 and 2002. The autopsy reports and clinical records were examined in those cases in which active tuberculosis was found. RESULTS: We found 92 cases of active tuberculosis, 57% corresponding to men. Mean age of this group was 64 years. A total of 20% of the patients died within 48 hours after admission. Predisposing factors were identified in 90% of the cases. Dyspnea (24% of cases) and wasting syndrome (23%) were the main symptoms that motivated patients to request medical attention. Up to 30% of cases had normal chest X-ray. Tuberculosis was suspected in only 46% of patients before death. Principal cause of death was tuberculosis in 61% of patients, 52% of patients had pulmonary tuberculosis, 28% suffered from miliary tuberculosis and 20% from extra-pulmonary tuberculosis. The lungs were the most frequently affected organ. Epithelioid granulomas were found in all patients. CONCLUSIONS: Tuberculosis is an uncommon finding in the autopsy as the cause of death. The presence of unspecific symptomatology, insufficient cost-effectiveness of the diagnostic tests and precocious death, are identified as the most frequent causes of undiagnosed tuberculosis.
Subject(s)
Autopsy , Tuberculosis/pathology , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Spain , Tuberculosis/epidemiologySubject(s)
Heart Septal Defects, Atrial/complications , Pulmonary Embolism/etiology , Stroke/etiology , Adult , Cerebral Angiography , Echocardiography , Fatal Outcome , Heart Septal Defects, Atrial/diagnostic imaging , Heart Septal Defects, Atrial/mortality , Humans , Male , Pulmonary Embolism/diagnostic imaging , Pulmonary Embolism/mortality , Stroke/diagnostic imaging , Stroke/mortality , Tomography, X-Ray ComputedABSTRACT
No disponible
No disponible
Subject(s)
Male , Adult , Humans , Pulmonary Embolism/diagnosis , Heart Septal Defects, Atrial/complications , Femoral Artery/physiopathology , Embolism, Paradoxical/physiopathologyABSTRACT
Since avascular necrosis of the bone was first described in a HIV infected patient in 1990, its incidence has increased, especially in recent years. The hip is most commonly involved and often bilaterally. We report a series of 5 cases of avascular necrosis of the bone in patients with HIV infection. Both hips were involved in 4 of the cases. All of them were receiving highly active antiretroviral treatment when avascular necrosis of the bone was diagnosed, and 4 of them presented at least one risk factor. The risk factors found in our series were: hyperlipidemia, use of corticosteroids and alcoholism. We cannot rule out antiretroviral treatment as a risk factor for avascular necrosis of the bone. Case-control studies published have not identified antiretroviral treatment as a risk factor probably due to small size of the samples.
Subject(s)
HIV Infections/complications , Osteonecrosis/complications , Adult , Case-Control Studies , Female , HIV Infections/epidemiology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Osteonecrosis/epidemiology , Osteonecrosis/pathology , PrevalenceABSTRACT
No disponible
Subject(s)
Humans , HIV Infections/complications , Organ Transplantation/standards , Liver Transplantation/standardsABSTRACT
We performed a retrospective study to identify the risk factors for cytomegalovirus (CMV) disease among 570 renal transplant recipients. By means of a multivariate analysis we identified antilymphocyte antibody therapy (odds ratio [OR]: 4.6; 95% confidence interval [CI]: 2.0 to 10.6), high doses of corticosteroids (OR: 3.4; 95% CI: 1.2 to 10.1), and double renal transplant (OR: 4.1; 95% CI: 1.5 to 11.5). To the best of our knowledge, this is the first study to suggest that in addition to other well-known risk factors for CMV disease (ie, therapy with anti-lymphocyte antibodies or high doses of corticosteroids), the use of double renal transplantation appears to increase the risk of CMV disease in this population.
